Multi-target modulation

"Multi-target modulation" refers to the pharmacological strategy of designing drugs (often called multi-target drugs or multi-target agents) that simultaneously modulate two or more molecular targets within a biological system[1][3][4][8]. Unlike traditional single-target approaches, this strategy aims to address the complexity of multifactorial diseases such as cancer, neurodegenerative disorders, psychiatric conditions, and metabolic syndromes by influencing multiple pathways at once[1][4][5][6]. Multi-target modulators can be single molecules designed to have activity at multiple protein targets or, in some cases, combination therapies. The approach seeks to enhance efficacy, reduce the risk of drug resistance, and minimize adverse effects related to polypharmacy[3][4][5][8]. However, "multi-target modulation" is *not* the name of a discrete molecule or protein; instead, it is a drug discovery approach or property. Therefore, it cannot be classified under molecular family, have a set of specific biological functions, or be associated with known interacting drugs as required for individual molecular targets[1][3][4][8]. Summary of findings: - "Multi-target modulation" is not a singular, defined molecular target but a general approach in drug development[1][3][4][8]. - It is not appropriate to use it as a structured molecular target entry. - Providing target-specific data (mechanism, biomarker, disease roles) is not possible because it does not refer to a specific molecule. If the intent is to extract data for actual targets that are commonly co-modulated in multi-target drug design (such as "Janus kinase 1" or "Peroxisome proliferator-activated receptor delta"), those would need to be specified individually.

Other names

Multi-target agentspolypharmacologymulti-target drugsmulti-target ligands